Recent Advances in Cancer Immunotherapy: Clinical Implications and Future Directions
Anisha Nallasamy
Shantha College of Physiotherapy, Affiliated to RGUHS, Bangalore, India.
Manju Rajput
GNIOT Institute of Medical Sciences and Research, Knowledge Park II, Greater Noida, Uttar Pradesh, India.
Zahid Ahmad Wani
Shantha College of Allied Health Science, Affiliated to RGUHS, Bangalore, India.
Maryam Khazir Dar
Noida International University, Uttar Pradesh, India.
Aakanksha
GNIOT Institute of Medical Sciences and Research, Knowledge Park II, Greater Noida, Uttar Pradesh, India.
Sheikh Hibban Fayaz
Shantha Group of Institutions, School of Allied Health Sciences, Affiliated to RGUHS, Bangalore, India.
Subiksha S
Shantha College of Allied Health Science, Affiliated to RGUHS, Bangalore, India.
Naveen H Simon *
Shantha Group of Institutions, Affiliated to RGUHS, Bangalore, India.
*Author to whom correspondence should be addressed.
Abstract
Cancer immunotherapy has transformed cancer treatment by harnessing the immune system to recognize and eliminate cancer cells. Recent years have witnessed significant advancements in this field, including the development of immune checkpoint inhibitors, chimeric antigen receptor (CAR) T-cell therapy, cancer vaccines, and adoptive cell therapy. These approaches have shown promising results in clinical trials, leading to improved outcomes for cancer patients. This paper provides an in-depth overview of recent advances in cancer immunotherapy, their clinical implications, challenges, and future directions.
Keywords: Adoptive cell therapy, cancer immunotherapy, cancer vaccines, CAR T-cell therapy, Clinical implications, Immune checkpoint inhibitors